JP2021519285A5 - - Google Patents
Info
- Publication number
- JP2021519285A5 JP2021519285A5 JP2020551481A JP2020551481A JP2021519285A5 JP 2021519285 A5 JP2021519285 A5 JP 2021519285A5 JP 2020551481 A JP2020551481 A JP 2020551481A JP 2020551481 A JP2020551481 A JP 2020551481A JP 2021519285 A5 JP2021519285 A5 JP 2021519285A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- pharmaceuticals
- fluorophenyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650744P | 2018-03-30 | 2018-03-30 | |
| US62/650,744 | 2018-03-30 | ||
| PCT/IB2019/052601 WO2019186488A1 (en) | 2018-03-30 | 2019-03-29 | A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519285A JP2021519285A (ja) | 2021-08-10 |
| JP2021519285A5 true JP2021519285A5 (enExample) | 2022-04-06 |
Family
ID=66397350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551481A Pending JP2021519285A (ja) | 2018-03-30 | 2019-03-29 | ダブラフェニブ、トラメチニブ及びｅｒｋ阻害剤を含む医薬品の三重の組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210121460A1 (enExample) |
| EP (1) | EP3773586A1 (enExample) |
| JP (1) | JP2021519285A (enExample) |
| KR (1) | KR20200138303A (enExample) |
| CN (1) | CN111936141A (enExample) |
| AU (1) | AU2019246719B2 (enExample) |
| BR (1) | BR112020019577A2 (enExample) |
| CA (1) | CA3094780A1 (enExample) |
| CL (1) | CL2020002505A1 (enExample) |
| IL (1) | IL277380A (enExample) |
| MX (1) | MX2020010231A (enExample) |
| RU (1) | RU2020135055A (enExample) |
| WO (1) | WO2019186488A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230090389A1 (en) * | 2020-02-28 | 2023-03-23 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
| IL295626A (en) * | 2020-02-28 | 2022-10-01 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor |
| KR20240055721A (ko) * | 2021-06-24 | 2024-04-29 | 아사나 바이오사이언시스 엘엘씨 | Erk1/2 억제제 조합 요법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100883289B1 (ko) | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| DK3063143T3 (en) * | 2013-11-01 | 2018-08-20 | Novartis Ag | Amino heteroaryl benzamides as kinase inhibitors |
| CA2991805A1 (en) * | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| CN109715163B (zh) * | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
-
2019
- 2019-03-29 AU AU2019246719A patent/AU2019246719B2/en not_active Ceased
- 2019-03-29 MX MX2020010231A patent/MX2020010231A/es unknown
- 2019-03-29 CA CA3094780A patent/CA3094780A1/en active Pending
- 2019-03-29 WO PCT/IB2019/052601 patent/WO2019186488A1/en not_active Ceased
- 2019-03-29 BR BR112020019577-4A patent/BR112020019577A2/pt not_active Application Discontinuation
- 2019-03-29 CN CN201980021573.3A patent/CN111936141A/zh active Pending
- 2019-03-29 KR KR1020207030757A patent/KR20200138303A/ko not_active Withdrawn
- 2019-03-29 JP JP2020551481A patent/JP2021519285A/ja active Pending
- 2019-03-29 RU RU2020135055A patent/RU2020135055A/ru unknown
- 2019-03-29 EP EP19721810.0A patent/EP3773586A1/en not_active Withdrawn
- 2019-03-29 US US17/042,591 patent/US20210121460A1/en not_active Abandoned
-
2020
- 2020-09-15 IL IL277380A patent/IL277380A/en unknown
- 2020-09-28 CL CL2020002505A patent/CL2020002505A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013203637B2 (en) | Combination therapy for proliferative disorders | |
| JP7149076B2 (ja) | ブルトン型チロシンキナーゼ阻害剤の薬学的製剤 | |
| JP2019532051A5 (enExample) | ||
| CN102089007B (zh) | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 | |
| CN103096881B (zh) | 含有具有不愉快味道的药物的膜制剂 | |
| KR20170033358A (ko) | 브루톤 티로신 키나아제 저해제의 신규한 제제 | |
| CN112867512A (zh) | 联合疗法 | |
| JP2013507415A5 (enExample) | ||
| JP2021530513A5 (enExample) | ||
| JP2018168191A5 (enExample) | ||
| JP2021504384A5 (enExample) | ||
| JP2019517587A5 (enExample) | ||
| ES2574627T3 (es) | Formas de administración farmacéuticas que comprenden 5-cloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida | |
| JP2023510332A5 (enExample) | ||
| CN101068571A (zh) | 改善透粘膜给药制剂的吸收的方法 | |
| RU2020135055A (ru) | Тройная фармацевтическая комбинация, включающая дабрафениб, траметиниб и ингибитор erk | |
| JP2009517411A5 (enExample) | ||
| JP2013526579A5 (enExample) | ||
| US10695296B2 (en) | Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient | |
| WO2015134561A1 (en) | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection | |
| JP2024506385A5 (enExample) | ||
| JP2021503448A5 (enExample) | ||
| EA200701681A1 (ru) | Пероральная лекарственная форма, содержащая росиглитазон | |
| CN113557016A (zh) | 衣壳组装调节剂固体配制品 | |
| TW202430528A (zh) | Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑 |